Skip to nav Skip to content

Clinical Trial Search

292 Clinical Trials Found

Clinical Trial 23177

A Phase 3, Open-Label, Randomized Study of Sonrotoclax(BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia
Disease Site: Chronic Leukemia (CLL, CML), Lymphoid Leukemia
PI: Saeed, Hayder

Clinical Trial 23335

Disease Site: Multiple Myeloma
PI: Nguyen, Nina

Clinical Trial 22286

Disease Site: Leukemia, other
PI: Shah, Bijal

Clinical Trial 22485

Disease Site: Lip, Oral Cavity and Pharynx
PI: Chung, Christine

Clinical Trial 22595

Disease Site: Multiple Myeloma
PI: Paba Prada, Claudia

Clinical Trial 23059

A Randomized, Double-blind, Placebo-controlled Phase 3 Study of Tamibarotene Plus Azacitidine Versus Placebo Plus Azacitidine in Newly Diagnosed Adult Patients Selected for RARA-positive Higher-risk Myelodysplastic Syndrome
Disease Site: Myeloid and Monocytic Leukemia
PI: Sallman, David

Clinical Trial 23399

A Randomized Phase III Trial of Pre-Operative Compared to Post-Operative Stereotactic Radiosurgery in Patients with Resectable Brain Metastases
Disease Site: Brain and Nervous System, Brain metastasis
PI: Yu, Hsiang-Hsuan (Michael)

Clinical Trial 20752

A Phase 1 Study of Vyxeos Plus Gilteritinib in Relapsed or Refractory, FLT3-Mutated Acute Myeloid Leukemia
Disease Site: Leukemia, other, Myeloid and Monocytic Leukemia
PI: Chan, Onyee

Clinical Trial 21892

A Phase 2, Single-Arm, Open-Label Study using Itacitinib and Tafasitamab as Pre-Modulation in Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Receiving CAR-T-Cell Therapy
Disease Site: Non-Hodgkin's Lymphoma
PI: Jain, Michael

Clinical Trial 22078

ONC201 for the Treatment of Newly Diagnosed H3 K27M-mutant Diffuse Glioma Following Completion of Radiotherapy: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study
Disease Site: Brain and Nervous System
PI: Grogan, Patrick

Clinical Trial 21860

A Phase 3 Randomized Clinical Study of MK-4280A (coformulated favezelimab [MK-4280] plus pembrolizumab [MK-3475]) Versus Physician's Choice Chemotherapy in PD-(L)1-refractory, Relapsed or Refractory Classical Hodgkin Lymphoma (KEYFORM-008)
Disease Site: Lymphoma
PI: Saeed, Hayder

Clinical Trial 21131

A Phase II Randomized Trial of Adjuvant Therapy with Pembrolizumab After Resection of Recurrent/Second Primary Head and Neck Squamous Cell Carcinoma with High Risk Features
Disease Site: Larynx, Lip, Oral Cavity and Pharynx, Head & Neck, Mouth, lip, nasal cavity
PI: Kirtane, Kedar